Daniel Kanmert

Daniel Kanmert serves as the Director of Medical Communications and Publications for Alnylam Pharmaceuticals, where responsibilities include the development and execution of long-range publication and communication strategies within the TTR Franchise. Prior to this role, Daniel held various leadership positions at Proteostasis Therapeutics, Inc., including Director of Scientific Communications and Manager of Scientific Communications, focusing on company-wide initiatives and enhancing scientific communications. Earlier experience includes a field-based role as a Clinical Trial Educator and a Scientist engaged in analytical techniques for clinical trials. Daniel's academic background features a Postdoctoral Fellowship in Neuroscience from Harvard Medical School and a PhD in Protein Chemistry from Linköping University.